drugset / Trial / NCT01018953
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-12
- Completion
- 2011-01
Outcome
Outcome not reported
Stopped: “Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ONZIGOLIDE | Unknown | 1 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 2 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 4 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 6 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 8 mg | Subcutaneous |